Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Actelion Pharmaceuticals Ltd.

http://www1.actelion.com/en/index.page

Latest From Actelion Pharmaceuticals Ltd.

Glenmark Initiates US Plant Cutback, Pins Hopes On gFlovent, Other Filings

Glenmark impairs oral solid dosage and nebulizer blocks at US manufacturing site amid tough market conditions. Can the firm's thrust on injectables and new respiratory filings including for generic Flovent, alongside leadership change, lift the US business?

Commercial Compliance

First Results Keep AstraZeneca’s Hopes High For Oral PCSK9 Inhibitor

AstraZeneca is looking to speed AZD0780 into Phase III development after it achieved a 78% total LDL cholesterol reduction in a Phase I study when used in combination with rosuvastatin. The firm needs to play catch up with its oral rivals.

Clinical Trials Companies

China Approval For Akeso’s Bispecific But ASCO Data Unnerve Investors

Ivonescimab in combination with chemotherapy reduced the risk of disease progression or death by 54% versus placebo in EGFR-mutated, non-squamous NSCLC after failed EGFR inhibitor treatment. However, the progression-free survival data did little to satisfy investors’ demand for clear benefits versus competitors. 

China Approvals

China Biotech CEO Interview: Starting A CNS Venture In An Economic Downturn

From Wyeth/Pfizer to Jiangsu Hengrui to IMab to starting her own biotech, Joan Huaqiong Shen has seen many ups and downs of drug development in China. She sat down with Scrip on the sidelines of the recent DIA China meeting to discuss her latest startup devoted to novel small molecules to treat schizophrenia and epilepsy and a gene therapy for ALS.

China Research & Development
See All

Company Information

  • Other Names / Subsidiaries
    • Ceptaris Therapeutics, Inc. (Yaupon Therapeutics, Inc.)
    • CoTherix, Inc
UsernamePublicRestriction

Register